Get the Facts
The drug manufacturer, Reckitt Benckiser, has agreed to pay the U.S. government $1.4 billion to settle allegations that it downplayed the risk of addiction of its medication Suboxone. The Department of Justice states that the British manufacturer marketed their drug as a less addictive drug and safer than ones that were on the market that is intended to treat opioid withdrawal. Reckitt Benckiser is a former subsidiary of Indivior, Inc. which is also in the spotlight in the opioid crisis. Reckitt Benckiser promoted a film version of Suboxone to healthcare providers as a less-abusable drug to treat opioid withdrawals when in fact, it was not.
